DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

Por Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Publicado no Br J Cancer (2016)

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

Por Verset, G, Verslype, C, Reynaert, H, Borbath, I, Langlet, P, Vandebroek, A, Peeters, M, Houbiers, G, Francque, S, Arvanitakis, M, Van Laethem, J-L
Publicado em 2007